> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Revokes 5 Covid Test EUAs
- URL: https://www.fdaweb.com/fda-revokes-5-covid-test-euas/
- Published: 2022-01-21T12:00:00.000Z
- Updated: 2026-09-14T17:29:29.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150974

*Federal Register* notice: FDA is announcing the revocation of the Emergency Use Authorizations (EUAs) issued to Cellex Inc. for the Cellex q–SARS–CoV–2 IgG/IgMRapid Test, BioMerieux SA for the SARS–COV–2 R–GENE, Siemens Healthcare Diagnostics Inc. for the Atellica IM SARS–CoV–2 IgG (COV2G), Siemens Healthcare Diagnostics Inc. for the Advia Centaur SARS–CoV–2 IgG, and Cepheid for the XpertOmni SARS–CoV–2\. FDA revoked the EUAs after the companies notified it that the tests were no longer marketed, distributed or supported and requested they be revoked. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-01-21/pdf/2022-01139.pdf?ref=fdaweb.com).